Angiotensin II Infusion — Competitive Intelligence Brief

Angiotensin II Infusion (Angiotensin II Infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor agent. Area: Cardiovascular / Critical Care.

marketed Vasopressor agent Angiotensin II receptor (AT1 and AT2) Cardiovascular / Critical Care Small molecule

Target snapshot

Angiotensin II Infusion (Angiotensin II Infusion) — Massachusetts General Hospital. Angiotensin II directly binds to angiotensin II receptors (AT1 and AT2) on vascular smooth muscle and other tissues to increase vasoconstriction and blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Angiotensin II Infusion TARGET	Angiotensin II Infusion	Massachusetts General Hospital	marketed	Vasopressor agent	Angiotensin II receptor (AT1 and AT2)
Vasopressin, Arginine	Vasopressin, Arginine	Lars Wiuff Andersen	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)
Vasopressin intravenous infusion	Vasopressin intravenous infusion	University of Sao Paulo	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptor V1a, V1b, and V2
Intracervical injection of Vasopressin	Intracervical injection of Vasopressin	Prisma Health-Upstate	marketed	Vasopressor agent	V1 vasopressin receptor
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
Administration of AVP	Administration of AVP	Assistance Publique - Hôpitaux de Paris	phase 3	Vasopressor agent	V1 and V2 vasopressin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor agent class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Hospital do Coracao · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. Prisma Health-Upstate · 1 drug in this class
5. The Cleveland Clinic · 1 drug in this class